Cloudbreak Pharma Inc. (HKG:2592)

Hong Kong · Delayed Price · Currency is HKD

1.190

+0.025 (2.15%)

Sep 9, 2026, 6:08 PM HKT

Market Cap	1.10B -74.0%
Revenue (ttm)	2.11M -97.4%
Net Income	-947.27M
EPS	-1.12
Shares Out	924.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,500
Open	1.190
Previous Close	1.165
Day's Range	1.190 - 1.190
52-Week Range	0.900 - 9.580
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About Cloudbreak Pharma

Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingre... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 61

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2592

Full Company Profile

Financial Performance

In 2025, Cloudbreak Pharma's revenue was $253,000, a decrease of -97.52% compared to the previous year's $10.21 million. Losses were -$67.66 million, -31.75% less than in 2024.

Financial numbers in USD Financial Statements